PSNLPersonalisPSNL info
$5.75info9.32%24h
Global rank14988
Market cap$281.93M
Change 7d50.52%
YTD Performance169.95%
SP500 benchmarkOutperform
P/E0
P/S0
Revenue$0
Earnings$0
Dividend yield-
Business data

    Personalis (PSNL) Stock Overview

    Personalis, Inc. operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies and large-scale genetic research programs. It offers NeXT Platform, which provides data analysis for tumor and its immune microenvironment, from a single limited tissue or plasma sample; ImmunoID Next for tumor profiling from tissue; NeXT Liquid Biopsy for tumor profiling from plasma; NeXT Personal, a liquid biopsy offering for personalized tumor tracking for patients; NeXT Dx Test, a genomic cancer profiling test to optimize therapy selection and match patients to clinical trials; and NeXT SHERPA and NeXT NEOPS for neoantigen prediction capabilities. The company also provides ACE platform for clinical and therapeutic applications, such as neoantigen prediction, biomarker identification, and novel drug target selection. It serves pharmaceutical, biopharmaceutical, diagnostic testing, and biotechnology companies; healthcare providers; universities; non-profits; and government entities. The company was incorporated in 2011 and is headquartered in Fremont, California.

    PSNL Stock Information

    Symbol
    PSNL
    Address
    1330 O’Brien DriveMenlo Park, CA 94025United States
    Founded
    -
    Trading hours
    -
    Website
    https://www.personalis.com
    Country
    🇺🇸 United States
    Phone Number
    650 752 1300

    Personalis (PSNL) Price Chart

    -
    Value:-

    Personalis Overview: Key Details and Summary

    Stock data
    2024
    Change
    Price
    $5.75
    N/A
    Market Cap
    $281.93M
    N/A
    Shares Outstanding
    49.03M
    N/A
    Employees
    395.00
    N/A
    logo
    Facebook Icon
    Twitter Icon
    Linkedin Icon
    © 2024 Topstocks.org